Amgen Inc. (AMGN) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - General Branche. Der Hauptsitz des Unternehmens ist in Thousand Oaks, CA, United States. Der aktuelle CEO ist Robert A. Bradway.
AMGN hat IPO-Datum 1983-06-17, 28,000 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $189.19B.
Amgen Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and delivers human therapeutics across key therapeutic areas including inflammation, oncology, bone health, cardiovascular disease, nephrology, and neuroscience. The company's extensive portfolio includes major brands such as Enbrel for rheumatoid arthritis and psoriasis, Neulasta for chemotherapy side effects, Prolia for osteoporosis, Repatha for cardiovascular risk reduction, and KYPROLIS for multiple myeloma, among many others. Amgen distributes its products through pharmaceutical wholesalers and direct-to-consumer channels to healthcare providers including physicians, hospitals, dialysis centers, and pharmacies worldwide. The company actively pursues strategic collaborations with leading pharmaceutical and biotechnology partners to advance its pipeline and expand treatment options across multiple disease areas. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen has established itself as a leader in the global biopharmaceutical industry.
